Cargando…

A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19

BACKGROUND: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. OBJECTIVE: The aim of this study was to evaluate the performances of a newly developed high t...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Jinwei, Chu, Eric, Zhang, Dayu, Lu, Chuanyi M., Zhang, Aiguo, Sha, Michael Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605757/
https://www.ncbi.nlm.nih.gov/pubmed/33152411
http://dx.doi.org/10.1016/j.jviromet.2020.114009
_version_ 1783604372309016576
author Du, Jinwei
Chu, Eric
Zhang, Dayu
Lu, Chuanyi M.
Zhang, Aiguo
Sha, Michael Y.
author_facet Du, Jinwei
Chu, Eric
Zhang, Dayu
Lu, Chuanyi M.
Zhang, Aiguo
Sha, Michael Y.
author_sort Du, Jinwei
collection PubMed
description BACKGROUND: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. OBJECTIVE: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection. RESULTS: Clinical agreement studies were performed in 107 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15 % (95 % CI: 19.22 % ∼74.87 %), 61.54 % (95 % CI: 31.58 % ∼86.14 %), and 97.53 % (95 % CI: 91.36 % ∼99.70 %) for samples collected on 0−7 days, 8−14 days, and ≥15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23 % (95 % CI: 95.53 % ∼99.52 %). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. CONCLUSION: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up anti-SARS-CoV-2 IgG testing.
format Online
Article
Text
id pubmed-7605757
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-76057572020-11-03 A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19 Du, Jinwei Chu, Eric Zhang, Dayu Lu, Chuanyi M. Zhang, Aiguo Sha, Michael Y. J Virol Methods Article BACKGROUND: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. OBJECTIVE: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection. RESULTS: Clinical agreement studies were performed in 107 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15 % (95 % CI: 19.22 % ∼74.87 %), 61.54 % (95 % CI: 31.58 % ∼86.14 %), and 97.53 % (95 % CI: 91.36 % ∼99.70 %) for samples collected on 0−7 days, 8−14 days, and ≥15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23 % (95 % CI: 95.53 % ∼99.52 %). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. CONCLUSION: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up anti-SARS-CoV-2 IgG testing. The Author(s). Published by Elsevier B.V. 2021-01 2020-11-02 /pmc/articles/PMC7605757/ /pubmed/33152411 http://dx.doi.org/10.1016/j.jviromet.2020.114009 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Du, Jinwei
Chu, Eric
Zhang, Dayu
Lu, Chuanyi M.
Zhang, Aiguo
Sha, Michael Y.
A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19
title A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19
title_full A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19
title_fullStr A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19
title_full_unstemmed A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19
title_short A high-throughput Anti-SARS-CoV-2 IgG testing platform for COVID-19
title_sort high-throughput anti-sars-cov-2 igg testing platform for covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605757/
https://www.ncbi.nlm.nih.gov/pubmed/33152411
http://dx.doi.org/10.1016/j.jviromet.2020.114009
work_keys_str_mv AT dujinwei ahighthroughputantisarscov2iggtestingplatformforcovid19
AT chueric ahighthroughputantisarscov2iggtestingplatformforcovid19
AT zhangdayu ahighthroughputantisarscov2iggtestingplatformforcovid19
AT luchuanyim ahighthroughputantisarscov2iggtestingplatformforcovid19
AT zhangaiguo ahighthroughputantisarscov2iggtestingplatformforcovid19
AT shamichaely ahighthroughputantisarscov2iggtestingplatformforcovid19
AT dujinwei highthroughputantisarscov2iggtestingplatformforcovid19
AT chueric highthroughputantisarscov2iggtestingplatformforcovid19
AT zhangdayu highthroughputantisarscov2iggtestingplatformforcovid19
AT luchuanyim highthroughputantisarscov2iggtestingplatformforcovid19
AT zhangaiguo highthroughputantisarscov2iggtestingplatformforcovid19
AT shamichaely highthroughputantisarscov2iggtestingplatformforcovid19